Literature DB >> 28951226

Deletion of JNK2 prevents vitamin-D-deficiency-induced hypertension and atherosclerosis in mice.

Jisu Oh1, Amy E Riek1, Rong M Zhang1, Samantha A S Williams1, Isra Darwech1, Carlos Bernal-Mizrachi2.   

Abstract

The c-Jun N-terminal kinase 2 (JNK2) signaling pathway contributes to inflammation and plays a key role in the development of obesity-induced insulin resistance and cardiovascular disease. Macrophages are key cells implicated in these metabolic abnormalities. Active vitamin D downregulates macrophage JNK activation, suppressing oxidized LDL cholesterol uptake and foam cell formation and promoting an anti-inflammatory phenotype. To determine whether deletion of JNK2 prevents high blood pressure and atherosclerosis known to be induced by vitamin D deficiency in mice, we generated mice with knockout of JNK2 in a background susceptible to diet-induced atherosclerosis (LDLR-/-). JNK2-/- LDLR-/- and LDLR-/- control mice were fed vitamin D-deficient chow for 8 weeks followed by vitamin D-deficient high fat diet (HFD) for 10 weeks and assessed before and after HFD. There was no difference in fasting glucose, cholesterol, triglycerides, or free fatty acid levels. However, JNK2-/- mice, despite vitamin D-deficient diet, had 20-30mmHg lower systolic (SBP) and diastolic (DBP) blood pressure before HFD compared to control mice fed vitamin D-deficient diets, with persistent SBP differences after HFD. Moreover, deletion of JNK2 reduced HFD-induced atherosclerosis by 30% in the proximal aorta when compared to control mice fed vitamin D-deficient diets. We have previously shown that peritoneal macrophages obtained from LDLR-/- mice fed vitamin D-deficient HFD diets have higher foam cell formation compared to those from mice on vitamin D-sufficient HFD. The increased total cellular cholesterol and modified cholesterol uptake in macrophages from mice on vitamin D-deficient HFD were blunted by deletion of JNK2. These data suggest that JNK2 signaling activation is necessary for the atherosclerosis and hypertension induced by vitamin D deficiency. Published by Elsevier Ltd.

Entities:  

Keywords:  Atherosclerosis; Hypertension; JNK; Macrophages; Vitamin D

Mesh:

Substances:

Year:  2017        PMID: 28951226      PMCID: PMC5826746          DOI: 10.1016/j.jsbmb.2017.09.014

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  46 in total

1.  Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study.

Authors:  Michel Brazier; Franck Grados; Saïd Kamel; Marc Mathieu; Alain Morel; Mohamed Maamer; Jean-Luc Sebert; Patrice Fardellone
Journal:  Clin Ther       Date:  2005-12       Impact factor: 3.393

2.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

Authors:  M Amine Bouhlel; Bruno Derudas; Elena Rigamonti; Rébecca Dièvart; John Brozek; Stéphan Haulon; Christophe Zawadzki; Brigitte Jude; Gérard Torpier; Nikolaus Marx; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

Review 3.  Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development.

Authors:  Y T Ip; R J Davis
Journal:  Curr Opin Cell Biol       Date:  1998-04       Impact factor: 8.382

4.  Effects of vitamin D supplementation on blood pressure.

Authors:  Sheng Hui Wu; Suzanne C Ho; Liu Zhong
Journal:  South Med J       Date:  2010-08       Impact factor: 0.954

5.  PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice.

Authors:  K Tordjman; C Bernal-Mizrachi; L Zemany; S Weng; C Feng; F Zhang; T C Leone; T Coleman; D P Kelly; C F Semenkovich
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 6.  Systematic review: Vitamin D and cardiometabolic outcomes.

Authors:  Anastassios G Pittas; Mei Chung; Thomas Trikalinos; Joanna Mitri; Michael Brendel; Kamal Patel; Alice H Lichtenstein; Joseph Lau; Ethan M Balk
Journal:  Ann Intern Med       Date:  2010-03-02       Impact factor: 25.391

7.  ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome.

Authors:  Jochen G Schneider; Brian N Finck; Jie Ren; Kara N Standley; Masatoshi Takagi; Kirsteen H Maclean; Carlos Bernal-Mizrachi; Anthony J Muslin; Michael B Kastan; Clay F Semenkovich
Journal:  Cell Metab       Date:  2006-11       Impact factor: 27.287

8.  Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants.

Authors:  Setor Kwadzo Kunutsor; Tanefa Antoinette Apekey; Marinka Steur
Journal:  Eur J Epidemiol       Date:  2013-03-02       Impact factor: 8.082

Review 9.  1,25(OH)2 vitamin D suppresses macrophage migration and reverses atherogenic cholesterol metabolism in type 2 diabetic patients.

Authors:  Amy E Riek; Jisu Oh; Carlos Bernal-Mizrachi
Journal:  J Steroid Biochem Mol Biol       Date:  2013-01-17       Impact factor: 4.292

10.  Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice.

Authors:  Sherry Weng; Jennifer E Sprague; Jisu Oh; Amy E Riek; Kathleen Chin; Miguel Garcia; Carlos Bernal-Mizrachi
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

View more
  2 in total

Review 1.  Genetic polymorphisms associated with reactive oxygen species and blood pressure regulation.

Authors:  Santiago Cuevas; Van Anthony M Villar; Pedro A Jose
Journal:  Pharmacogenomics J       Date:  2019-02-06       Impact factor: 3.550

2.  Correlation of Vitamin D with Inflammatory Cytokines, Atherosclerotic Parameters, and Lifestyle Factors in the Setting of Heart Failure: A 12-Month Follow-Up Study.

Authors:  Daniel N Roffe-Vazquez; Anna S Huerta-Delgado; Elena C Castillo; José R Villarreal-Calderón; Adrian M Gonzalez-Gil; Cecilio Enriquez; Gerardo Garcia-Rivas; Leticia Elizondo-Montemayor
Journal:  Int J Mol Sci       Date:  2019-11-19       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.